Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes

Immunology

Volumn 107, Issue 4, 2002, Pages 461-471

  Walsh, Patrick T ^a   Smith, Loraine M ^a   O'Connor, Rosemary ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CD28 ANTIGEN; DICOUMAROL; FAS ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AKT1 PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MORPHOLINE DERIVATIVE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; APOPTOSIS; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; METHODOLOGY; PHOSPHORYLATION; WESTERN BLOTTING;

ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; CHROMONES; DICUMAROL; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JURKAT CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, GROWTH FACTOR; T-LYMPHOCYTES;

EID: 0036884489     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01525.x     Document Type: Article

References (59)

1. Scaffidi C, Kirchhoff S, Krammer PH, Peter ME. Apoptosis signaling in lymphocytes. Curr Opin Immunol 1999; 11:277-85.
2. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5:625-30.
3. Hennino A, Berard M, Casamayor-Palleja M, Krammer PH, Defrance T. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J Immunol 2000; 165:3023-30.
4. Ward SG. CD28: a signalling perspective. Biochem J 1996; 318:361-77.
5. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995; 3:87-98.
6. Walsh PT, O'Connor R. The insulin-like growth factor-I receptor is regulated by CD28 and protects activated T cells from apoptosis. Eur J Immunol 2000; 30:1010-18.
7. Kooijman R, Rijkers GT, Zegers BJ. IGF-I potentiates interleukin-2 production in human peripheral T cells. J Endocrinol 1996; 149:351-6.
8. Kooijman R, Scholtens LE, Rijkers GT, Zegers BJ. Type I insulin-like growth factor receptor expression in different developmental stages of human thymocytes. J Endocrinol 1995; 147:203-9.
9. Kozak RW, Haskell JF, Greenstein LA, Rechler MM, Waldmann TA, Nissley SP. Type I and II insulin-like growth factor receptors on human phytohemagglutinin-activated T lymphocytes. Cell Immunol 1987; 109:318-31.
10. Krishnaraj R, Zaks A, Unterman T. Relationship between plasma IGF-I levels, in vitro correlates of immunity, and human senescence. Clin Immunol Immunopathol 1998; 88:264-70.
11. Tu W, Cheung PT, Lau YL. IGF-I increases interferon-gamma and IL-6 mRNA expression and protein production in neonatal mono-nuclear cells. Pediatr Res 1999; 46:748-54.
12. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96:2856-61.
13. Rodriguez-Tarduchy G, Collins MK, Garcia I, Lopez-Rivas A. Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol 1992; 149:535-40.
14. O'Connor R. Survival factors and apoptosis. Adv Biochem Eng Biotechnol 1998; 62:137-66.
15. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57:1050-93.
16. Dudek H, Datta SR, Franke TF et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275:661-5.
17. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41.
18. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-68.
19. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21:893-901.
20. Rohn JL, Hueber AO, McCarthy NJ, Lyon D, Navarro P, Burgering BM, Evan G. The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis. Oncogene 1998; 17:2811-8.
21. Kane LP, Andres PG, Howland KC, Abbas AK, Weiss A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol 2001; 2:37-44.
22. Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39.
23. Krause D, Lyons A, Fennelly C, O'Connor R. Transient activation of Jun N terminal kinases (JNKs) and protection from apoptosis by the IGF-IR can be suppressed by dicoumarol. J Biol Chem 2001; 276:19244-52.
24. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci 1999; 55:1230-54.
25. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410:37-40.
26. Rincon M, Flavell RA, Davis RA. The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Radic Biol Med 2000; 28:1328-37.
27. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 1994; 77:727-36.
28. Ghaffari-Tabrizi N, Bauer B, Villunger A, Baier-Bitterlich G, Altman A, Utermann G, Uberall F, Baier G. Protein kinase Ctheta, a selective upstream regulator of JNK/SAPK and IL-2 promoter activation in Jurkat T cells. Eur J Immunol 1999; 29:132-42.
29. Werlen G, Jacinto E, Xia Y, Karin M. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. Embo J 1998; 17:3101-11.
30. Dong C, Yang DD, Tournier C, Whitmarsh AJ, Xu J, Davis RJ, Flavell RA. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000; 405:91-4.
31. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA. Defective T cell differentiation in the absence of Jnk1. Science 1998; 282:2092-5.
32. Roulston A, Reinhard C, Amiri P, Williams LT. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 1998; 273:10232-9.
33. Huang Y, Hutter D, Liu Y, Wang X, Sheikh MSM, Chan A, Holbrook NJ. Transforming growth factor-beta 1 suppresses serum deprivation-induced death of A549 cells through differential effects on c-Jun and JNK activities. J Biol Chem 2000; 275:18234-42.
34. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD, Damsky CH. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH (2) -terminal kinase. J Cell Biol 2000; 149:741-54.
35. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS Jr. Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 2001; 25:25.
36. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 2001; 15:1419-26.
37. Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem 2001; 77:849-63.
38. Bruckner SR, Tammariello SP, Kuan CY, Flavell RA, Rakic P, Estus S. JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons. J Neurochem 2001; 78:298-303.
39. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 1995; 17:51-61.
40. Weiss L, Whitmarsh AJ, Yang DD, Rincon M, Davis RJ, Flavell RA. Regulation of c-Jun NH (2) -terminal kinase (Jnk) gene expression during T cell activation. J Exp Med 2000; 191:139-46.
41. Lawlor MA, Feng X, Everding DR, Sieger K, Stewart CE, Rotwein P. Dual control of muscle cell survival by distinct growth factor-regulated signaling pathways. Mol Cell Biol 2000; 20:3256-65.
42. 2-terminal kinase. J Exp Med 2000; 191:1017-30.
43. Shan X, Czar MJ, Bunnell SC, Liu PP, Liu Y, Schwartzberg PL, Wange RL. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol 2000; 20:6945-57.
44. Madge LA, Pober JS. A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-I, inhibits apoptosis but does not activate NFkappaB in human endothelial cells. J Biol Chem 2000; 275:15458-65.
45. Matsuzaki H, Tamatani M, Mitsuda N, Namikawa K, Kiyama H, Miyake S, Tohyama M. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem 1999; 73:2037-46.
46. Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL, Pommier JG. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 2000; 60:2007-17.
47. Harada Y, Tanabe E, Watanabe R et al. Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation. J Biol Chem 2001; 276:9003-8.
48. Baserga R, Resnicoff M, D'Ambrosio C, Valentinis B. The role of the IGF-I receptor in apoptosis. Vitam Horm 1997; 53:65-98.
49. Niesler CU, Urso B, Prins JB, Siddle K. IGF-I inhibits apoptosis induced by serum withdrawal, but potentiates TNF-alpha-induced apoptosis, in 3T3-L1 preadipocytes. J Endocrinol 2000; 167:165-74.
50. Niikura T, Hashimoto Y, Okamoto T et al. Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner. J Neurosci 2001; 21:1902-10.
51. Nishina HK, Fischer D, Radvanyi L et al. Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nature 1997; 385:350-3.
52. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 1996; 271:31929-36.
53. Abreu-Martin MT, Palladino AA, Faris M, Carramanzana NM, Nel AE, Targan SR. Fas activates the JNK pathway in human colonic epithelial cells: lack of a direct role in apoptosis. Am J Physiol 1999; 27:599-605.
54. Hofmann TG, Moller A, Hehner SP, Welsch D, Droge W, Schmitz ML. CD95-induced JNK activation signals are transmitted by the death-inducing signaling complex (DISC), but not by Daxx. Int J Cancer 2001; 93:185-91.
55. Villunger AD, Huang C, Holler N, Tschopp J, StrasSeries A. Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD. J Immunol 2000; 165:1337-43.
56. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87:565-76.
57. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell ; Biol 1999; 19:1938-49.
58. Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. Embo J 1997; 16:2634-45.
59. Shapiro VS, Mollenauer MN, Weiss A. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. Blood 2001; 98:187-93.